CA2271652A1 - Compact member comprising a plurality of porous cellulose matrices, (pcms), method of manufacturing and use thereof - Google Patents

Compact member comprising a plurality of porous cellulose matrices, (pcms), method of manufacturing and use thereof Download PDF

Info

Publication number
CA2271652A1
CA2271652A1 CA002271652A CA2271652A CA2271652A1 CA 2271652 A1 CA2271652 A1 CA 2271652A1 CA 002271652 A CA002271652 A CA 002271652A CA 2271652 A CA2271652 A CA 2271652A CA 2271652 A1 CA2271652 A1 CA 2271652A1
Authority
CA
Canada
Prior art keywords
release
pcms
compact member
active compound
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002271652A
Other languages
English (en)
French (fr)
Inventor
Torkel Gren
Christer Nystrom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9604124A external-priority patent/SE9604124D0/xx
Application filed by Individual filed Critical Individual
Publication of CA2271652A1 publication Critical patent/CA2271652A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Manufacture Of Porous Articles, And Recovery And Treatment Of Waste Products (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
CA002271652A 1996-11-12 1997-11-12 Compact member comprising a plurality of porous cellulose matrices, (pcms), method of manufacturing and use thereof Abandoned CA2271652A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE9604124-9 1996-11-12
SE9604124A SE9604124D0 (sv) 1996-11-12 1996-11-12 Compact member, method of manufacturing and use thereof
US3172396P 1996-11-25 1996-11-25
US60/031,723 1996-11-25
PCT/SE1997/001901 WO1998020858A1 (en) 1996-11-12 1997-11-12 COMPACT MEMBER COMPRISING A PLURALITY OF POROUS CELLULOSE MATRICES, (PCMs), METHOD OF MANUFACTURING AND USE THEREOF

Publications (1)

Publication Number Publication Date
CA2271652A1 true CA2271652A1 (en) 1998-05-22

Family

ID=26662794

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002271652A Abandoned CA2271652A1 (en) 1996-11-12 1997-11-12 Compact member comprising a plurality of porous cellulose matrices, (pcms), method of manufacturing and use thereof

Country Status (6)

Country Link
EP (1) EP0941069A1 (de)
JP (1) JP2001503766A (de)
AU (1) AU728754B2 (de)
CA (1) CA2271652A1 (de)
NZ (1) NZ335737A (de)
WO (1) WO1998020858A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2360655C (en) * 1999-01-29 2007-03-20 Losan Pharma Gmbh Pharmaceutical compositions
DE60021570T2 (de) * 1999-06-07 2006-05-24 Altana Pharma Ag Neue zubereitung und darreichungsform enthaltend einen säurelabilen protonenpumpeninhibitor
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
US7001475B2 (en) 2001-12-11 2006-02-21 3M Innovative Properties Company Film structures and methods of making film structures
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
US20040109889A1 (en) 2002-12-04 2004-06-10 Bunick Frank J. Surface treatment composition for soft substrates
DE102005028696A1 (de) * 2005-06-21 2006-12-28 Pulmotec Gmbh Verwendung eines Hilfsstoffs zur Einstellung der Abrasionsfestigkeit eines verfestigten Wirkstoffpräparats
EP2191848A4 (de) * 2007-08-31 2013-05-15 Daiichi Sankyo Co Ltd Zubereitung mit verzögerter freisetzung und herstellungsverfahren dafür

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9002017D0 (sv) * 1990-06-06 1990-06-06 Kabivitrum Ab Process for manufacture of matrices
DE69114006T2 (de) * 1990-06-20 1996-05-02 Advanced Polymer Systems Inc Zusammensetzungen und verfahren für die kontrollierte freisetzung von löslichen wirkstoffen.
SE9301220D0 (sv) * 1993-04-14 1993-04-14 Kabi Pharmacia Ab Manufacturing matrices

Also Published As

Publication number Publication date
AU5075898A (en) 1998-06-03
AU728754B2 (en) 2001-01-18
WO1998020858A1 (en) 1998-05-22
JP2001503766A (ja) 2001-03-21
NZ335737A (en) 2000-09-29
EP0941069A1 (de) 1999-09-15

Similar Documents

Publication Publication Date Title
US4748023A (en) Process for the preparation of sustained release pharmaceutical compositions having a high active ingredient content
US4708874A (en) Devices for the controlled release of active substances, as well as process for the preparation thereof
Hilton et al. In vitro and in vivo evaluation of an oral sustained-release floating dosage form of amoxycillin trihydrate
CA1201064A (en) Constant release rate solid oral dosage formulations of drugs having a pk.sub.a7-10 and an aqueous solubility of 15-100 g/ml water
JP5170723B2 (ja) 活性薬剤の制御放出用錠剤
JPS63258407A (ja) 徐放性カプセル
US8703203B2 (en) Oral dosage form of deferasirox
WO1998009597A2 (en) Cushioning beads and tablet comprising the same capable of forming a suspension
HRP980379A2 (en) Sertraline salts and sustained-release dosage forms of sertraline
JP2008510000A (ja) 制御放出性ナノ粒子有効薬剤配合物投与剤型品および方法
US7364755B2 (en) Modified calcium phosphate excipient
DE19931708A1 (de) Verfahren zur Herstellung schnell zerfallender, fester pharmazeutischer Zubereitungen
US20130039982A1 (en) Low-dose tablets and preparation process
AU728754B2 (en) Compact member comprising a plurality of porous cellulose matrices, (PCMs), method of manufacturing and use thereof
US6322813B1 (en) Compact member, method of manufacturing and use thereof
Danckwerts Development of a zero-order release oral compressed tablet with potential for commercial tabletting production
Shotton et al. Effect of intragranular and extragranular disintegrating agents on particle size of disintegrated tablets
Malamataris et al. Sustained release from matrix system comprising hydrophobia and hydrophilic (gel-forming) parts
JP2001335469A (ja) 固体製剤の製造方法
Bredenberg New Concepts in Administration of Drugs in Tablet Form: Formulation and Evaluation of a Sublingual Tablet for Rapid Absorption, and Presentation of an Individualised Dose Administration System
KR0137270B1 (ko) 트리메부틴의 서방형 조성물 및 그 제조 방법
KR950007097B1 (ko) 서방성 캡슐
Bashaiwoldu Studies on the influence of composition and processing on the mechanical properties of pellets and compacted pellets
Louw Evaluation and comparison of magnesium stearate and sodium stearyl fumarate (Pruv) as lubricants in directly compressible tablet formulations: their effect on tablet properties and drug dissolution
Mohammed et al. Effect of a co-processed excipient on the disintegration and drug release profile of ibuprofen tablets

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued